News | June 04, 2012

Jury Awards $6.4 Million for Heart Attack Misdiagnosis

ER doctors misdiagnosed heart condition, released man with Motrin and antibiotic

June 4, 2012 — A jury awarded $6.4 million to the young children of a Philadelphia man after finding that emergency room doctors misdiagnosed a heart condition as pneumonia and discharged him from the hospital, only for him to die months later.

After seven days of testimony, the jury found that Robert M. McNamara, M.D., Marsha W. Edwards, M.D. and Temple University Hospital were negligent in the care of Derrick Harlem, 38. The verdict is believed to be among the largest Pennsylvania medical malpractice awards involving a death in years. Jurors reached the verdict three years to the day after Harlem's misdiagnosed heart condition.

"This is a fair and just verdict," said Matthew Casey, a founding partner at Ross Feller Casey, LLP, who litigated the case on behalf of Harlem's children. "These young children lost their dad and no amount of money can replace him. They would gladly give the money back for more time with their dad."

On May 31, 2009, Harlem passed out while playing basketball and was transported to the Temple University Hospital’s emergency department. Despite symptoms consistent with a heart attack, Harlem was diagnosed with pneumonia and released later that day after being given Motrin and Azithromycin.

Three months later, Harlem again passed out while playing basketball and was again taken to Temple's emergency department. This time, he had suffered a massive heart attack as a result of what had become a complete arterial blockage. Harlem remained in a pharmacologically induced coma until his death Nov. 12, 2009. He left behind five children, now ages 3-11.

The verdict includes $5.5 million for the loss of guidance, tutelage and moral upbringing.

For more information: www.rossfellercasey.com/practice-areas/medical-malpractice/

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init